Search
Nov 19, 2024
London Healthcare Week: VectorY Therapeutics is delivering antibodies to the CNS using an AAV vector - the first program for ALS is scheduled to go into the clinic next year
CEO Sander van Deventer describes the science behind delivering antibodies this way, and learnings he has taken away from the gene...
Nov 18, 2024
From Japan, Takeda's CEO Christophe Weber talks about the company's Japanese roots, but global transformation - plus, five key pipeline assets
He describes Takeda's HQ and R&D facilities in Japan, but also how global markets have grown to dominate the company's business since he...
Nov 18, 2024
Mursla Bio presented data at The Liver Meeting suggesting that its EvoLiver diagnostic test can spot liver cancer among cirrhotic patients with 86% early-stage sensitivity and 88% specificity
CEO Pierre Arsѐne describes how the test analyses hepatocyte extracellular vesicles, and how he believes this result surpasses the...
Nov 18, 2024
London Healthcare Week: The CEO of MoonLake Immunotherapeutics gives an overview of the company's Nanobody platform, including the lead program that targets IL-17A and IL-17F
Jorge Santos da Silva explains the properties that he believes give Nanobodies versatility and an edge over traditional antibodies, and...
Nov 18, 2024
Sagimet Biosciences presented a subset analysis of the FASCINATE-2 P2 trial of denifanstat in MASH patients at The Liver Meeting showing improved fibrosis based on an AI pathology analysis method
CEO David Happel describes how this fatty acid synthase (FASN) inhibitor works, and the AI method suggesting the therapy is having an...
Nov 17, 2024
With programs using both somatic cells and iPSCs, and an NK platform for oncology in the works, Japan's Healios aims to be a leader in regenerative medicine
CEO Hardy Kagimoto describes the company's programs, including how Multistem could soon be conditionally approved in Japan and is...
Nov 16, 2024
In a post-hoc analysis of 89bio's ENLIVEN phase 2b trial of pegozafermin presented at The Liver Meeting, data suggested that the therapy reduced progression to cirrhosis for MASH patients
CEO Rohan Palekar describes this result that was presented at the meeting, as well as other biomarker findings. Plus, he highlights three...
Nov 14, 2024
An overview of Chugai, including its global ambitions and R&D capabilities, with the company’s CEO, Dr. Osamu Okuda, in Tokyo
Dr. Okuda describes Chugai’s vision to be a Top Innovator in 2030, the science that the company excels in, including unique midsize...
Nov 14, 2024
Microbiotica is working on microbiome therapies in Cambridge, UK, with lead programs in immuno-oncology and inflammatory bowel disease
CEO Tim Sharpington describes the advances that have been made in the microbiome field over the last decade and introduces us to...
Nov 14, 2024
Cambridge, UK based Mestag Therapeutics last month announced a license and research collaboration with MSD to leverage the company's fibroblast platform to find inflammatory disease targets
CEO Susan Hill describes the role that fibroblasts play in regulating immune responses to inflammatory conditions and how Mestag is...
Nov 13, 2024
Tokyo based TMS has a lead program that aims to be the first new medicine for acute ischemic stroke in decades
CEO Takuro Wakabayashi describes the unmet need in stroke and how this asset found its way into to a partnership with RTW-based Corxel....
Nov 13, 2024
Tokyo based Heartseed is leveraging its expertise iPSCs and regenerative medicine to solve unmet needs in cardiovascular disease like heart failure
Founder and CEO Keiichi Fukuda describes the qualities that Heartseed has built into the cardiomyocytes it is developing to make them...
Nov 9, 2024
SITC 2024: Aulos Bioscience CEO Aron Knickerbocker describes the phase 1 and preliminary phase 2 data for the company's IL-2 redirecting antibody
He describes the safety and preliminary efficacy they have seen, including how patients are experiencing a lowering of Tregs. Plus, the...
Nov 9, 2024
SITC 2024: Marengo's CEO Zhen Su discusses the first-in-human data for the company's lead program, Invikafusp Alfa
He describes how this dual T-cell agonist is designed to cause the expansion and reprogramming of TIL's in the body. Plus, an update on...
Nov 9, 2024
SITC 2024: Compugen's CEO discusses ovarian cancer data for her company's TIGIT + PVRIG + pembro triplet combo
Anat Cohen-Dayag describes this SITC data, shares her opinion on the TIGIT field, and highlights an IL-18 program that is partnered with...
Nov 9, 2024
SITC 2024: Immatics CEO Harpreet Singh shares an update on clinical data presented at SITC for the company's Gen 1 and Gen 2 PRAME cell therapies
He describes the Gen 1 data in melanoma and more, and compares it to what we have seen with competitor TIL data. Also, why the Gen 2...
Nov 8, 2024
SITC 2024: With a TIL therapy having made it to the market for the first time this year, the CEO of KSQ Therapeutics describes what the next generation of TILs might look like
Qasim Rizvi says he believes TILs can have broad applicability in the solid tumor space. He describes how KSQ is knocking out SOCS1 and...
Nov 7, 2024
Texas Life Science Forum: Reglagene is aiming to get tubulin therapies across the blood brain barrier so they can treat brain cancers
CEO Richard Austin explains how the company hopes to acheive this with a small molecule therapy. Plus, why he moved the company from...
Nov 7, 2024
Texas Life Science Forum: 4M Therapeutics is aiming make therapies for the CNS that are safer and more tolerable than current treatments
CEO Pablo Lapeurta, previously CMO of Lexicon, describes the lead programs for biopolar disorder and Alzheimer's agitation. Plus, Houston...
Nov 7, 2024
Texas Life Science Forum: March Biosciences closed a $28.4M series A round last month to advance its CD5 targeting CAR-T
CEO Sarah Hein describes the rationale for CD5, and share her experience of what it was like making the raise come together. Brought to...
.png){kind=logo}
